← Pharmacy curriculum
Module 16410 lessonsRxPrep 2023 Chapter 23, reconciled with the 2023 ESC endocarditis guideline and 2025 corrigendum, 2023 Duke-ISCVID diagnostic criteria, the 2025 AHA blood culture-negative endocarditis statement, current AHA dental prophylaxis guidance, and current FDA labeling

Infective Endocarditis

Recognize the syndrome, preserve microbiologic evidence, image the infected surface, construct pathogen-specific bactericidal therapy, identify surgical disease, and close the loop from bloodstream clearance to recurrence prevention.

01

Connect endothelial injury, bacteremia, microbial adhesion, vegetation, valve destruction, and embolization.

02

Use blood cultures and the 2023 Duke-ISCVID framework without substituting criteria for judgment.

03

Sequence TTE, TEE, repeat studies, cardiac CT, nuclear imaging, and extracardiac imaging.

04

Design empiric therapy from valve type, acquisition, prior exposure, allergy, organ function, and local ecology.

05

Select current streptococcal and HACEK regimens with susceptibility and duration boundaries.

06

Prefer beta-lactams for MSSA, manage MRSA exposure, and avoid outdated routine native-valve aminoglycosides.

07

Use dual beta-lactam enterococcal therapy and expert pathways for VRE, non-HACEK gram-negative, and fungal disease.

08

Recognize heart failure, uncontrolled infection, embolic risk, prosthetic disease, and device extraction needs.

09

Build inpatient, OPAT, and selected oral consolidation monitoring around named decisions.

10

Apply current highest-risk dental prophylaxis criteria and prevent recurrence through oral health and follow-up.

164.01

Build the Infection From Surface to System

IE begins when a susceptible endocardial or prosthetic surface meets sustained or transient bloodstream organisms that can adhere, proliferate, and resist host clearance.

What to learn
  • Endothelial injury
  • Vegetation
  • Biofilm
  • Valve destruction
  • Embolization
Vegetation biologyFollow infection from injured surface to systemic injury
01SurfaceEndothelial injury

A susceptible native or prosthetic surface collects platelet and fibrin.

02SeedBacteremia

Circulating organisms reach and adhere to the thrombotic surface.

03ShelterVegetation

Dense growth inside matrix resists immune clearance and drug penetration.

04DamageValve and emboli

Destruction causes regurgitation while fragments seed distant organs.

Build the vegetation

Endothelial injury promotes platelet and fibrin deposition. Bacteremia introduces organisms with adhesion traits, and the growing vegetation shelters a dense microbial population.

Separate left from right

Left-sided infection can cause systemic emboli and valve failure. Tricuspid and other right-sided infection often produces septic pulmonary emboli.

Recognize risk without stereotyping

Prosthetic valves, prior IE, CIEDs, congenital or structural disease, vascular access, dialysis, healthcare exposure, and injection exposure change probability but do not replace evidence.

Respect the quiet presentation

Fever is common, but a new murmur and classic peripheral findings are not required. Subacute fatigue, weight loss, anemia, renal findings, back pain, or emboli can be the first signal.

0 of 1 answered
01Which sequence best explains vegetation formation?
Answer every question to submit.
164.02

Preserve the Organism Before Treating the Syndrome

Microbiology directs curative therapy. Modern diagnosis uses three culture sets, the 2023 Duke-ISCVID framework, molecular and tissue methods, and a staged blood culture-negative pathway.

What to learn
  • Three culture sets
  • 2023 Duke-ISCVID
  • Persistent bacteremia
  • BCNE
  • Molecular diagnosis
Evidence architecturePreserve the organism and classify the complete syndrome
01CultureThree sets first

Adequate pretherapy volume protects diagnostic yield.

02Classify2023 Duke-ISCVID

Microbiology, imaging, surgery, pathology, and minor findings combine.

03TrackClearance

Repeat cultures expose persistent endovascular infection.

04ExpandBCNE pathway

After 72 hours, add exposure-guided serology, molecular work, and tissue planning.

Collect cultures first

Obtain three adequately filled blood culture sets from peripheral sites before antibiotics when the patient is stable enough to wait. Bottle volume and prior antimicrobial exposure strongly affect yield.

Use the current criteria

The 2023 Duke-ISCVID criteria retain definite, possible, and rejected categories while expanding typical organisms, molecular methods, prosthetic and device imaging, and surgical evidence.

Document clearance

Repeat cultures every 24 to 48 hours until negative. Persistent recovery requires reassessment of exposure, resistance, abscess, hardware, metastatic foci, and source control.

Escalate culture-negative work

When cultures remain negative after 72 hours, expand exposure-guided serology, molecular testing, valve-tissue planning, pathology, and noninfectious mimics with infectious diseases and microbiology expertise.

0 of 1 answered
01What is the best initial microbiologic step in a stable patient with suspected IE and no prior antibiotics?
Answer every question to submit.
164.03

Image the Valve, Then Image the Consequences

Echocardiography establishes valve and device anatomy, while repeat and multimodality imaging answer questions that one negative study cannot settle.

What to learn
  • TTE
  • TEE
  • Repeat imaging
  • Cardiac CT and nuclear imaging
  • Embolic survey
Imaging ladderEscalate from valve anatomy to hidden extension and emboli
01ScreenTTE

Define valve function, vegetation, and hemodynamics.

02ResolveTEE

See prostheses, devices, small lesions, and perivalvular disease.

03RepeatEvolving biology

A negative early study may become diagnostic later.

04ExtendCT and nuclear imaging

Answer prosthetic, anatomic, or extracardiac questions.

Start with TTE

Obtain TTE promptly to assess vegetation, regurgitation, ventricular function, hemodynamics, and gross complications.

Escalate to TEE

Use TEE when TTE is negative or inconclusive despite high suspicion and in prosthetic valves, intracardiac devices, S. aureus bacteremia, suspected complications, or surgical planning.

Repeat when biology evolves

Repeat TTE or TEE in 5 to 7 days, or sooner with clinical change, when initial imaging is negative but suspicion remains high.

Add a modality with purpose

Cardiac CT can define perivalvular anatomy. FDG PET CT and WBC imaging can strengthen prosthetic or device assessment. Brain and body imaging can uncover silent emboli and metastatic infection.

Do not anticoagulate the vegetation

IE alone is not an indication to begin antithrombotic therapy. Stroke type, hemorrhage, prosthetic indication, and surgery require multidisciplinary decisions.

0 of 1 answered
01What should follow a negative TTE in a patient with a prosthetic valve and persistent S. aureus bacteremia?
Answer every question to submit.
164.04

Treat Early Without Freezing the Empiric Regimen

Empiric treatment protects the patient before identification, but it must be tailored to valve type, acquisition, prior therapy, allergy, organ function, and local resistance, then narrowed quickly.

What to learn
  • Valve type
  • Acquisition
  • Bactericidal exposure
  • De-escalation
  • Duration clock
Treatment engineMove from probability to verified definitive exposure
01SampleCultures

Preserve microbiology before therapy when safe.

02CoverPhenotype

Valve type and acquisition define initial threats.

03VerifyExposure

Dose, organs, MIC, interactions, and delivery determine activity.

04NarrowDefinitive regimen

Replace empiric breadth within 24 to 48 hours when possible.

Do not universalize one combination

Stable community native-valve disease differs from early prosthetic, device, healthcare-associated, or septic disease. Vancomycin plus ceftriaxone is not a universal answer.

Protect the cultures

Draw cultures before therapy when safe. Unstable sepsis, shock, acute valve failure, or neurologic emergency requires prompt treatment after rapid specimen collection.

Verify exposure

Use weight, kidney and liver function, infusion strategy, susceptibility, AUC or levels when indicated, drug interactions, and dose receipt to confirm that an active drug is truly active in the patient.

Narrow with ownership

Change empiric therapy to the most effective and least toxic organism-specific regimen as soon as identification and susceptibility permit.

Count from effective therapy

Duration usually begins with effective therapy and bloodstream clearance. Surgery does not automatically restart a full course unless operative cultures or other findings justify it.

0 of 1 answered
01Which factor set should determine the empiric IE regimen?
Answer every question to submit.
164.05

Use Susceptibility to Shorten or Simplify Safely

Oral streptococci, Streptococcus gallolyticus, and HACEK organisms have reliable treatment pathways, but valve type, MIC, complications, kidney function, and source evaluation control the details.

What to learn
  • Viridans streptococci
  • Penicillin G
  • Ceftriaxone
  • Gentamicin boundary
  • HACEK
Susceptibility pathwaysLet MIC, valve material, and toxicity set duration
01IdentifyOral streptococci

Use penicillin or ceftriaxone for a valve-specific duration.

02SelectSynergy

Reserve gentamicin for uncomplicated low-risk native-valve disease.

03InvestigateS. gallolyticus

Connect the bloodstream isolate to colon evaluation.

04TreatHACEK

Use ceftriaxone and distinguish it from non-HACEK disease.

Treat susceptible oral streptococci

Use penicillin G 12 to 18 million units daily or ceftriaxone 2 g daily for four weeks in uncomplicated native-valve disease and generally six weeks with prosthetic material.

Limit two-week synergy

A two-week beta-lactam plus gentamicin regimen is only for carefully selected uncomplicated susceptible native-valve disease with preserved kidney function and no extracardiac complication.

Investigate S. gallolyticus

Arrange colon evaluation after stabilization because bacteremia or IE has an important association with colorectal neoplasia.

Treat HACEK with ceftriaxone

Ceftriaxone 2 g daily is commonly used for four weeks in native-valve and six weeks in prosthetic-valve HACEK IE. Use ampicillin only when susceptibility is established.

0 of 1 answered
01Which patient is the best candidate for a two-week beta-lactam plus gentamicin streptococcal regimen?
Answer every question to submit.
164.06

Prefer the Strongest Staphylococcal Drug and Remove Old Toxicity

S. aureus and coagulase-negative staphylococci can destroy valves rapidly, seed distant sites, persist on hardware, and expose outdated habits such as routine native-valve gentamicin.

What to learn
  • MSSA
  • MRSA
  • Vancomycin AUC
  • Daptomycin
  • Prosthetic biofilm
Staphylococcal decisionsChoose the strongest drug and remove old toxicity
01PreferMSSA beta-lactam

Switch from empiric vancomycin when susceptibility permits.

02MeasureMRSA exposure

Use AUC-guided vancomycin or syndrome-matched daptomycin.

03AvoidRoutine gentamicin

Native-valve benefit is unproven and kidney harm increases.

04CoordinateProsthetic infection

Time rifampin after clearance and evaluate surgery and biofilm.

Switch MSSA to a beta-lactam

Use nafcillin or oxacillin 2 g every 4 hours, or cefazolin 2 g every 8 hours when appropriate, generally for six weeks. Do not keep vancomycin without a compelling reason.

Treat MRSA with verified exposure

Use vancomycin with current AUC-guided practice or daptomycin. FDA-labeled daptomycin is 6 mg/kg daily for S. aureus bacteremia including right-sided IE, while guidelines may use higher doses for difficult MRSA or enterococcal disease.

Remove routine native-valve gentamicin

Aminoglycosides do not improve established outcomes in staphylococcal native-valve IE and increase kidney injury.

Handle prosthetic infection as a team

Rifampin is reserved for susceptible foreign-body infection and is generally delayed until 3 to 5 days of effective therapy after bacteremia clears. Its evidence is weak and its interactions are substantial. Routine adjunctive gentamicin benefit is also uncertain.

Investigate every persistent culture

Search for abscess, infected hardware, metastatic foci, inadequate exposure, resistance, and delayed surgery rather than merely adding drugs.

0 of 1 answered
01What should happen when native-valve cultures identify MSSA and beta-lactams are tolerated?
Answer every question to submit.
164.07

Create Synergy Without Losing the Patient

Enterococci require combination logic, while VRE, non-HACEK gram-negative organisms, and fungi require specialized susceptibility, exposure, surgery, and toxicity planning.

What to learn
  • Ampicillin and ceftriaxone
  • HLAR
  • VRE
  • Non-HACEK gram negative
  • Fungal IE
Difficult pathogen logicCreate synergy while protecting organs and future options
01PairAmpicillin and ceftriaxone

Complementary PBP binding treats susceptible E. faecalis.

02ConfirmHLAR status

Aminoglycoside synergy fails with high-level resistance.

03DesignVRE pathway

Use species, MIC, exposure, combination, and source control.

04EscalateRare pathogens

Non-HACEK and fungi demand specialist and surgical planning.

Use dual beta-lactam therapy for E. faecalis

Ampicillin 2 g every 4 hours plus ceftriaxone 2 g every 12 hours, commonly for six weeks, provides complementary PBP saturation and avoids prolonged aminoglycoside toxicity.

Use aminoglycoside synergy selectively

Verify absence of high-level resistance and monitor levels, kidneys, hearing, and vestibular symptoms if an ampicillin or penicillin plus gentamicin pathway is chosen.

Escalate VRE expertise

Use species, van genotype, daptomycin MIC, prior exposure, and source control to design high-dose daptomycin combination or linezolid-based therapy when appropriate.

Do not collapse rare pathogens together

Non-HACEK gram-negative IE often needs combination and surgery assessment. Fungal IE usually requires early surgery plus prolonged species-directed antifungal therapy and sometimes suppression.

0 of 1 answered
01Which regimen is appropriate for susceptible E. faecalis IE with high-level aminoglycoside resistance and kidney vulnerability?
Answer every question to submit.
164.08

Recognize When Antibiotics Cannot Repair Anatomy

Heart failure, uncontrolled infection, embolic risk, prosthetic destruction, and infected cardiac hardware require early surgical and multidisciplinary decisions rather than an antibiotic-only plan.

What to learn
  • Heart failure
  • Abscess
  • Persistent infection
  • Embolic prevention
  • Device extraction
Surgical triggersRecognize when drugs cannot repair infected anatomy
01PumpHeart failure

Severe acute valve dysfunction demands urgent review.

02ControlPersistent infection

Abscess, fistula, hardware, and bacteremia may require removal.

03ProtectEmbolic risk

Balance vegetation anatomy against neurologic timing.

04ExtractCIED infection

Remove the complete infected system and plan reimplantation deliberately.

Operate for mechanical failure

Acute severe regurgitation, obstruction, fistula, pulmonary edema, or shock requires urgent surgical evaluation while active therapy continues.

Control infection that cannot be sterilized

Abscess, pseudoaneurysm, fistula, dehiscence, new conduction disease, enlarging vegetation, resistant organisms, and persistent cultures can require removal of infected tissue.

Balance embolic prevention with neurologic risk

Vegetation size and mobility, prior emboli, organism, valve dysfunction, ischemic or hemorrhagic stroke, mycotic aneurysm, and operative feasibility determine timing.

Extract infected CIED systems

Definite device infection generally requires complete system extraction, cultures, antimicrobial treatment, temporary rhythm support when necessary, and delayed need-based reimplantation.

Treat the whole person

Include substance use treatment, pain and withdrawal care, harm reduction, housing, access, patient goals, and stigma-free communication in the curative plan.

0 of 1 answered
01What is the priority when IE causes acute severe regurgitation and pulmonary edema?
Answer every question to submit.
164.09

Make Every Trend Lead to a Decision

IE monitoring must detect microbiologic failure, mechanical deterioration, embolization, organ toxicity, exposure failure, line harm, and barriers before the patient becomes unstable.

What to learn
  • Culture clearance
  • Drug exposure
  • Organ toxicity
  • OPAT
  • Oral consolidation
Decision monitoringConvert every trend into a threshold, action, and owner
01ClearCultures

Document bloodstream sterilization and investigate persistence.

02ProtectOrgans

Follow drug-specific kidney, liver, blood, nerve, muscle, and ECG risk.

03ConsolidateOPAT or oral

Move out only after complications and surgery are controlled.

04CompleteVerified outcome

Close doses, response, valve plan, access, and recurrence education.

Monitor the infection and the host

Follow cultures, fever, hemodynamics, examination, CBC, kidney and liver function, inflammatory trajectory, ECG or CK when indicated, new focal symptoms, and valve function.

Interpret drug levels in context

Use current vancomycin AUC-guided practice when feasible. Interpret gentamicin levels only with exact dose and sampling times, and monitor kidney, hearing, and vestibular function.

Use outpatient therapy as consolidation

Consider OPAT or selected oral step-down only after cultures clear, critical complications are controlled, surgery is addressed, the regimen is reliable, monitoring is accessible, and rapid return is possible.

Protect the access plan

Choose the safest delivery route, monitor line complications and adherence, reconcile interactions, and establish missed-dose and symptom escalation pathways.

Close completion deliberately

Confirm dose delivery, culture and clinical response, complication resolution, follow-up imaging plan, valve function, dental care, treatment record, and recurrence instructions.

0 of 1 answered
01When is outpatient or selected oral consolidation most appropriate?
Answer every question to submit.
164.10

Prevent the Cases Prevention Can Actually Reach

Modern prevention prioritizes oral health and reserves a single antibiotic dose for highest-risk cardiac conditions undergoing qualifying dental procedures.

What to learn
  • Highest-risk cardiac conditions
  • Qualifying dental procedures
  • Amoxicillin
  • Allergy alternatives
  • No routine nondental prophylaxis
Prevention boundaryUse oral health broadly and antibiotics narrowly
01ConfirmCardiac eligibility

Restrict prophylaxis to highest-risk conditions.

02ConfirmDental exposure

Gingiva, periapical tissue, or oral mucosal perforation must be involved.

03DoseOne preprocedure regimen

Use amoxicillin or a current allergy and route alternative.

04SustainOral health

Regular care and rapid fever evaluation matter beyond one procedure.

Identify highest-risk conditions

Prophylaxis is reasonable for prosthetic valves including transcatheter prostheses and homografts, prosthetic valve-repair material, prior IE, defined congenital disease, and transplant valve regurgitation from a structurally abnormal valve.

Identify qualifying dental procedures

The procedure must manipulate gingival tissue, the periapical region, or perforate oral mucosa. Routine radiographs, orthodontic adjustment, deciduous tooth shedding, and noninfected anesthetic injection do not qualify.

Use one preprocedure dose

Give amoxicillin 2 g orally 30 to 60 minutes before the procedure. If oral dosing is impossible, use ampicillin 2 g IM or IV, or cefazolin or ceftriaxone 1 g IM or IV when appropriate.

Update the allergy pathway

Oral alternatives include cephalexin 2 g, azithromycin or clarithromycin 500 mg, or doxycycline 100 mg. Avoid cephalosporins after penicillin anaphylaxis, angioedema, or urticaria. Clindamycin is no longer recommended.

Do not extend prophylaxis indiscriminately

Routine prophylaxis is not recommended for TEE, upper or lower endoscopy, colonoscopy, or cystoscopy without active infection. Oral health and regular dental care provide the broader prevention foundation.

0 of 1 answered
01Which adult regimen is standard for an eligible patient before qualifying dental work?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 180 question bank.

180 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. 2023 ESC Guidelines for the Management of Endocarditis
  2. 2023 Duke-ISCVID Diagnostic Criteria
  3. AHA Blood Culture-Negative Endocarditis Scientific Statement
  4. AHA Prevention of Infective Endocarditis Wallet Card
  5. ACC and AHA Valvular Heart Disease Guideline
  6. DailyMed Daptomycin Label
PharmacyOpen tools